Drugs that contain Dexmedetomidine Hydrochloride
1. Drug name - DEXMEDETOMIDINE HYDROCHLORIDE
| Patent Number | Company | Patent Title | Patent Expiry | Activity Alert |
|---|---|---|---|---|
| These patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc). | ||||
| US9649296 | HQ SPCLT PHARMA | Heat sterilizeable, premixed, ready to use dexmedetomidine solution packaged in a flexible plastic container |
Apr, 2036
(13 years from now) | |
| US9717796 | HQ SPCLT PHARMA | Heat sterilizeable, premixed, ready to use dexmedetomidine solution packaged in a flexible plastic container |
Apr, 2036
(13 years from now) | |
Treatment: NA
Dosage: SOLUTION;INTRAVENOUS
More Information on Dosage
| Strength | Dosage | Availability |
|---|---|---|
| EQ 1MG BASE/10ML (EQ 100MCG BASE/ML) | SOLUTION;INTRAVENOUS | Prescription |
| EQ 200MCG BASE/50ML (EQ 4MCG BASE/ML) | SOLUTION;INTRAVENOUS | Prescription |
| EQ 400MCG BASE/4ML (EQ 100MCG BASE/ML) | SOLUTION;INTRAVENOUS | Prescription |
| EQ 400MCG BASE/100ML (EQ 4MCG BASE/ML) | SOLUTION;INTRAVENOUS | Prescription |
2. Drug name - PRECEDEX
| Patent Number | Company | Patent Title | Patent Expiry | Activity Alert |
|---|---|---|---|---|
| These patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc). | ||||
| US8455527 | HOSPIRA | Methods of treatment using a dexmedetomidine premix formulation |
Jan, 2032
(9 years from now) | |
| US8648106 | HOSPIRA | Dexmedetomidine premix formulation |
Jan, 2032
(9 years from now) | |
| US9616049 | HOSPIRA | Dexmedetomidine premix formulation |
Jan, 2032
(9 years from now) | |
| US8242158 | HOSPIRA | Dexmedetomidine premix formulation |
Jan, 2032
(9 years from now) | |
| US10016396 | HOSPIRA | Dexmedetomidine premix formulation |
Jan, 2032
(9 years from now) | |
| US9320712 | HOSPIRA | Dexmedetomidine premix formulation |
Jan, 2032
(9 years from now) | |
| US8338470 | HOSPIRA | Dexmedetomidine premix formulation |
Jan, 2032
(9 years from now) | |
|
US8648106
(Pediatric) | HOSPIRA | Dexmedetomidine premix formulation |
Jul, 2032
(9 years from now) | |
|
US8242158
(Pediatric) | HOSPIRA | Dexmedetomidine premix formulation |
Jul, 2032
(9 years from now) | |
|
US8455527
(Pediatric) | HOSPIRA | Methods of treatment using a dexmedetomidine premix formulation |
Jul, 2032
(9 years from now) | |
|
US8338470
(Pediatric) | HOSPIRA | Dexmedetomidine premix formulation |
Jul, 2032
(9 years from now) | |
|
US9320712
(Pediatric) | HOSPIRA | Dexmedetomidine premix formulation |
Jul, 2032
(9 years from now) | |
|
US9616049
(Pediatric) | HOSPIRA | Dexmedetomidine premix formulation |
Jul, 2032
(9 years from now) | |
Treatment: Use for sedation
Dosage: INJECTABLE;INJECTION
More Information on Dosage
| Strength | Dosage | Availability |
|---|---|---|
| EQ 1MG BASE/250ML (EQ 4MCG BASE/ML) | INJECTABLE;INJECTION | Prescription |
| EQ 80MCG BASE/20ML (EQ 4MCG BASE/ML) | INJECTABLE;INJECTION | Prescription |
| EQ 200MCG BASE/2ML (EQ 100MCG BASE/ML) | INJECTABLE;INJECTION | Prescription |
| EQ 200MCG BASE/50ML (EQ 4MCG BASE/ML) | INJECTABLE;INJECTION | Prescription |
| EQ 400MCG BASE/100ML (EQ 4MCG BASE/ML) | INJECTABLE;INJECTION | Prescription |
availability in other generic markets.
Click on the highlighted region to filter.